HTB

PK and drug interactions

Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy

Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates

Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen

Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole  

Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults 

No clinically relevant reduction in oral cabotegravir when co-administered with rifabutin  

Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin

Efavirenz side effects and other drug-drug interactions are common in Ugandan cohort

Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily 

Vaginal ring reduces efavirenz but not atazanavir exposures 

Efavirenz might decrease effectiveness of the vaginal contraceptive ring

Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6

Twice-daily bictegravir does not overcome drug interaction with rifampicin

Twice-daily dolutegravir is effective and tolerable with rifampicin 

Significant drug-drug interaction between dolutegravir and isoniazid-rifapentine

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

Dolutegravir pharmacokinetics in pregnancy

FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

New HIV diagnoses in children in UK and Ireland continue to decline

World Health Organisation paediatric dosing tool

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Use of modelling to predicting paediatric dosing of long acting antiretrovirals

Nevirapine dosing for treatment of neonates

Pharmacokinetics of old and new TB drugs for children

The effects of systemic efavirenz exposure, sex and age on risk of viral non-suppression

Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB

Reducing efavirenz dose is unlikely to overcome interaction with levonorgestrel

Doravirine and cabotegravir do not affect the pharmacokinetics of oral contraceptives

Pharmacokinetics of four antiretrovirals in pregnancy: data from the PANNA network

Dolutegravir placental transfer moderate in ex vivo model

Paediatric dosing of DRV/r

Elvitegravir in children and adolescents

PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir

Pharmacokinetics in pregnancy: darunavir/r and etravirine

Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

Pharmacokinetics and safety of moxifloxacin in children

Equivalent efficacy with lower dose darunavir

Pharmacokinetic targets for efavirenz might be too high

Preventing and treating TB in children – more baby steps

Pharmacokinetics of etravirine with once-daily and twice-daily dosing

Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above

Bilirubin as a surrogate marker for atazanavir in children

Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia

Tenofovir population pharmacokinetics in pregnancy

Effect of rifampicin on BMS-663068 in HIV negative volunteers

Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting

Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections

Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years

Pharmacokinetics of currently available antiretroviral options for young children

Safety of transplacental raltegravir in neonates and washout pharmacokinetics

Dietary requirements changed in Europe for fixed dose combination rilpivirine/tenofovir/FTC (Eviplera)

Paediatric TB: glimpses of PK data and a potential new approach to drug development

Efavirenz interaction studies with TB compounds bedaquiline and delamanid

Ritonavir significantly increases exposure to colchicine (gout)

Ritonavir interaction with quinine is clinically insignificant but may warrant caution

Case report: fluticasone, fluconazole and ritonavir interactions

Case reports of complications from ketamine use in two MSM on ritonavir-based combinations

Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations

13th International workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2012, Barcelona

Post navigation